Argenx announces positive chmp opinion for subcutaneous efgartigimod for generalized myasthenia gravis

Amsterdam, the netherlands— september 15 , 2023 —argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the committee for medicinal products for human use (chmp) of the european medicines agency (ema) has recommended ec approval of the sc injectable formulation of efgartigimod as an add on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive. sc efgartigimod is formulated with halozyme's enhanze® drug delivery technology to facilitate subcutaneous delivery of biologics.
ARGX Ratings Summary
ARGX Quant Ranking